Women across the UK could benefit from better research into the safety and effectiveness of medicines and medical devices following the launch of a new Women’s Health Programme by the Medicines and Healthcare products Regulatory Agency (MHRA).
The initiative, announced on 16 November 2026, aims to address longstanding gaps in medical research that have left important questions unanswered about how treatments affect women at different stages of their lives, particularly during pregnancy, breastfeeding, reproductive health and menopause.
The scale of the problem was highlighted by an MHRA analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023. According to the regulator, pregnant women were represented in just 1.1% of the trials, while breastfeeding women were represented in only 0.6%.
Although women account for approximately 51% of the UK population, their health needs have not always been adequately reflected in the research used to assess medicines and medical devices. The MHRA hopes its new programme will help close those evidence gaps, improve understanding of treatment risks and benefits, and support the development of healthcare products that better meet women’s needs.
Why the UK is launching a new Women’s Health Programme
Medical treatments are often developed and assessed using evidence gathered through clinical trials. These studies help researchers understand whether medicines and medical devices work, what risks they carry and how different groups of patients may respond.
However, when certain populations are excluded or poorly represented, doctors and patients can be left with limited evidence about the most appropriate treatment options.
For women, these gaps can be especially important during pregnancy and breastfeeding, when healthcare professionals must consider the wellbeing of both the patient and, where relevant, the developing baby.
The problem extends beyond maternity care. Some conditions affect women differently from men, while others are more common among women or involve health needs that have historically received less research attention.
Factors such as age, hormonal changes, reproductive health, existing medical conditions and biological differences can influence how people respond to medicines.
The MHRA’s new programme is intended to strengthen the scientific evidence available to regulators, researchers and healthcare professionals so that treatment decisions can be informed by a better understanding of these differences.
Pregnant and breastfeeding women remain underrepresented in clinical trials
One of the most striking findings behind the programme concerns the limited representation of pregnant and breastfeeding women in clinical research.
The MHRA examined 4,616 UK clinical trial applications submitted between 2019 and 2023 and found that pregnant women were represented in only 1.1% of trials. Breastfeeding women were represented in just 0.6%.
These percentages refer to the proportion of trials in which the groups were represented, rather than the proportion of all trial participants who were pregnant or breastfeeding.
The findings highlight a challenge in medical research. Pregnancy and breastfeeding can affect how medicines are absorbed, distributed and processed by the body, yet the available evidence for these populations is often limited.
Researchers must also consider important ethical and safety issues when designing studies involving pregnant or breastfeeding participants. The MHRA’s programme is intended to encourage more appropriate and inclusive research while maintaining safeguards for participants.
Better evidence could help healthcare professionals make more informed decisions when patients need treatment during pregnancy or while breastfeeding.
However, the launch of the programme does not mean that existing medicines have suddenly become unsafe or that patients should stop taking prescribed treatments.
Anyone who is pregnant, breastfeeding or planning a pregnancy should speak with an appropriate healthcare professional before changing or discontinuing medication.
Government says women’s health has been overlooked for too long
Women’s Health Minister Baroness Gillian Merron welcomed the programme, saying women had historically been underrepresented in the research used to shape the treatments and medical devices they rely on.
She said the government was determined to address these gaps and described the initiative as part of a wider effort to ensure healthcare services respond more effectively to women’s needs.
The programme will contribute to the government’s renewed Women’s Health Strategy for England, alongside related work taking place in Scotland, Wales and Northern Ireland.
MHRA Chief Executive Lawrence Tallon said improving understanding of how medicines and medical devices affect women presents both a scientific challenge and an opportunity to develop more personalised healthcare.
He explained that stronger evidence could help identify important differences in treatment responses, support researchers and innovators, and improve the information available when assessing the benefits and risks of healthcare products.
The regulator plans to work with patients, healthcare professionals, researchers and industry representatives to strengthen the evidence base while maintaining standards for medicine and medical device safety, quality and effectiveness.
What could the programme mean for everyday healthcare?
For patients, the programme’s long-term aim is to support better-informed treatment decisions and encourage the development of healthcare products that reflect women’s experiences and medical needs.
This could be relevant to a wide range of health issues, including reproductive healthcare, menopause, long-term conditions and the management of illnesses that may affect women differently.
Women experiencing symptoms that are difficult to explain or treat may also benefit from research that considers differences in how conditions develop and how treatments work across patient groups.
For example, the evidence needed to assess a medicine for a woman managing a chronic condition during pregnancy may differ from the evidence needed for someone who is not pregnant.
Similarly, medical devices developed for reproductive healthcare or conditions associated with ageing may need to account for differences in patients’ needs and experiences.
The MHRA says improving the quality of evidence can help regulators make more informed decisions and give researchers clearer direction when developing new treatments.
Nevertheless, the programme is a research and regulatory initiative rather than an immediate change to NHS treatment eligibility, prescribing rules or access to individual medicines.
UK FemTech industry could benefit from stronger research
The announcement also highlights the commercial opportunities associated with women’s health technology.
The UK’s growing FemTech sector, which develops technologies and services addressing women’s health needs, already generates nearly £300 million in annual turnover, according to figures cited by the MHRA.
FemTech includes innovations associated with reproductive health, fertility, menstrual health, menopause, long-term conditions and healthy ageing.
The sector has attracted increasing interest as researchers, technology companies and investors recognise that women’s health needs have not always received the same attention as other areas of healthcare innovation.
By working with developers earlier and providing clearer expectations about the evidence needed to demonstrate safety and effectiveness, the MHRA hopes to support responsible innovation and help promising products progress through regulatory pathways.
This does not mean that products will receive approval automatically or that safety requirements will be relaxed.
Instead, the regulator says it wants to encourage innovation while ensuring that decisions remain grounded in reliable scientific evidence.
Health Research Authority calls for more inclusive clinical trials
The Health Research Authority (HRA) has welcomed the programme and emphasised the importance of ensuring clinical research reflects the populations who may eventually use new treatments.
Naho Yamazaki, the HRA’s Deputy Director of Policy and Partnerships, said researchers should consider groups that have traditionally been underrepresented when designing clinical studies.
The HRA and MHRA have already developed joint guidance on Inclusion and Diversity Plans, intended to help researchers consider who should be represented in studies from the earliest stages of research design.
This includes women and girls, as well as people who are pregnant or breastfeeding where their inclusion is relevant and appropriate.
More representative research can improve understanding of how treatments perform across different populations and help reduce gaps in the evidence used to make healthcare decisions.
The programme also places importance on patient involvement, recognising that people with lived experience of health conditions can help identify problems and priorities that may otherwise receive insufficient attention.
According to the MHRA, the initiative was shaped through engagement with its Patient and Public Community and a focus group delivered by the Patients Association.
Better evidence could improve access to women’s health treatments
The Consumer Healthcare Association, PAGB, has also welcomed the programme, saying stronger evidence could help women make informed decisions about their health and support appropriate innovation.
Its Chief Executive, Michelle Riddalls OBE, highlighted recent changes that have allowed certain low-dose vaginal oestrogen products to become more accessible through pharmacy supply arrangements.
These developments have expanded options for some women seeking treatment for menopausal symptoms, subject to the conditions and professional advice associated with the products.
The association believes that improving the evidence available to regulators could support future decisions about whether other suitable medicines can be made more accessible.
However, any changes to how medicines are classified or supplied would still require regulatory assessment, including consideration of safety, appropriate use and the needs of patients.
The MHRA’s wider objective is to ensure that new scientific evidence can inform regulatory decisions while maintaining public confidence in the medicines and devices available in the UK.
Programme launched during London Life Sciences Week
The Women’s Health Programme was announced at the inaugural DIA-MHRA Global Summit, held in London on 16 and 17 November 2026 as part of London Life Sciences Week.
The event brings together regulators, researchers, pharmaceutical companies, healthcare professionals and patient representatives to discuss how international cooperation can support medical innovation.
Women’s health is one of several areas receiving attention during the week, alongside clinical research, artificial intelligence, advanced treatments, manufacturing and rare diseases.
The initiative is also the first part of a broader MHRA effort to address health inequalities under its 2030 Strategy.
The regulator has scheduled a webinar for 9 December 2026, from 11am to midday, to introduce the programme and explain its plans for improving evidence, supporting innovation and strengthening women’s health outcomes.
The success of the initiative will depend on whether it leads to more inclusive research, stronger evidence about treatment safety and effectiveness, and practical improvements in healthcare over time.
What the new programme means for Nigerian and African women in the UK
For Nigerian and other African women living in Britain, the MHRA’s announcement raises an important question about whose experiences are reflected in medical research and whether available evidence adequately represents women from different ethnic backgrounds.
The low participation figures for pregnant and breastfeeding women matter to Nigerian mothers managing health conditions during pregnancy, including those who need ongoing medication or specialist treatment. When research evidence is limited, patients and clinicians may face more uncertainty about the benefits and risks of particular medicines.
The programme also creates an opportunity to examine whether clinical trials include women from Black African backgrounds in sufficient numbers to identify differences that may be clinically relevant. However, ethnicity alone does not determine how someone responds to treatment, and meaningful research must consider factors such as age, underlying health conditions, genetics, socioeconomic circumstances and access to healthcare.
For Nigerian women who feel that concerns about menstrual health, menopause, persistent pain or reproductive symptoms have not been adequately addressed, the wider emphasis on listening to patients is particularly relevant. Women should feel able to describe their symptoms clearly, ask about treatment options and request further assessment when problems persist.
Language differences, unfamiliarity with the NHS and concerns about discussing sensitive health issues can sometimes make these conversations more difficult. Patients can ask healthcare professionals for explanations they understand and request appropriate communication support when needed.
Nigerian women working in UK healthcare, medical research, pharmaceuticals and health technology may also have opportunities to contribute professional expertise to more inclusive study design, patient engagement and the development of women’s health products. The announcement does not establish a dedicated funding or recruitment scheme for diaspora professionals, but it highlights areas in which research and innovation are receiving greater attention.
For women interested in participating in clinical research, the practical starting point is to ask healthcare professionals about suitable studies or consult recognised UK research information services. Participation should always be voluntary and based on clear information about the study’s purpose, potential risks and safeguards.
At Chijos News, we will continue to examine whether changes in Britain’s healthcare research system translate into better experiences for Nigerian and African women, particularly in maternity care, reproductive health, menopause and the treatment of long-term conditions. The real measure of progress will be whether women who have historically been overlooked are included appropriately in research, whether their concerns influence the development of treatments and whether they receive clearer, more reliable information when making decisions about their health.